Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Dec 2024 value amounting to $3.8 million.

  • Rocket Pharmaceuticals' Gains from Investment Securities was N/A to $3.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is 615.38% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Gains from Investment Securities of $3.8 million as of Q4 2024, which was up 3,706.73% from -$104,000 recorded in Q3 2024.
  • In the past 5 years, Rocket Pharmaceuticals' Gains from Investment Securities ranged from a high of $20.2 million in Q1 2020 and a low of -$2.9 million during Q2 2024.
  • For the 3-year period, Rocket Pharmaceuticals' Gains from Investment Securities averaged around $2.2 million, with its median value being $366,000 (2022).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Gains from Investment Securities spiked by 73,156.95% in 2023, and later crashed by 509.96% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $6.4 million in 2020, then decreased by 18.67% to $5.2 million in 2021, then reached $29,000 in 2022, then skyrocketed by 2,324.14% to $703,000 in 2023, then slumped by 509.96% to $3.8 million in 2024.
  • Its Gains from Investment Securities was $3.8 million in Q4 2024, compared to -$104,000 in Q3 2024 and -$2.9 million in Q2 2024.